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Aspirin-pretreated, a2p-prelabeled, washed human platelets resuspended in a buffer containing apyrase and 2% plasma 
were exposed to epinephrine and the Ca z+ ionophore A23187. Epinephrine potentiated platelet aggregation ( ot secre- 
tion), the production of pzP]phosphatidic acid and myosin light chain phosphorylation induced by A23187. No phos- 
phorylation of the 40 kDa protein, the substrate ofprotein kinase C, was observed. We conclude that G~-protein activa- 
tion evoked by epinephrine and Ca 2+ mobilization caused by A23187 represents a novel synergism for platelet aggre- 
gation and that protein kinase C activation, under these conditions i  not needed for platelet aggregation. 
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1. INTRODUCTION 
Ca 2+ mobilization and protein kinase C activa- 
tion are two known pathways mediating platelet 
activation by physiological agonists that activate 
phospholipase C [1]. Ca 2+ ionophores and protein 
kinase C activators ynergize in inducing platelet 
aggregation and secretion [2], and we could 
demonstrate recently that Ca 2+ mobilization 
primes protein kinase C in human platelets leading 
to increased aggregation and secretion [3]. 
Epinephrine as a physiological platelet stimulus 
is unique. It does not induce phospholipase C ac- 
tivation in human platelets, if the formation or ac- 
tion of positive feedback stimulators uch as ADP 
and endoperoxides/thromboxane A2 is inhibited 
[4]. Also, epinephrine does not - in aspirinized 
platelets - elevate significantly cytosolic Ca 2+ and 
activate Ca2+-dependent kinases and protein 
kinase C [5]. Epinephrine binds to cr2-adrenocep- 
tors on human platelets [6,7]. These are coupled to 
the guanine nucleotide-binding protein Gi which 
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mediates inhibition of adenylate cyclase [8,9]. 
However, inhibition of adenylate cyclase is not the 
mechanism by which epinephrine induces and 
potentiates aggregation [10-12]. Thus, the effector 
mechanism by which tr2-adrenoceptor activation 
causes and potentiates platelet aggregation is not 
known. 
We have observed recently that oe2-adrenoceptor 
agonists, known to interact with Gi, synergized 
with the protein kinase C pathway in inducing 
platelet aggregation. The synergism of epinephrine 
and protein kinase C activators in inducing platelet 
aggregation involved a novel mechanism [5]. The 
present study was undertaken to determine 
whether and how te2-adrenoceptor activation by 
epinephrine would synergize with the Ca 2÷ 
pathway stimulated by Ca 2+ ionophores in human 
platelets. 
2. MATERIALS AND METHODS 
2.1. Materials 
[32p]Orthophosphate was obtained from NEN (Boston, 
MA). Acetylsalicylic acid, A23187, prostaglandin E1(PGE0, 
prostacyclin (PGI2), 1-epinephrine bitartrate and apyrase (A 
6132) were from Sigma (St. Louis, MO). Indo-l/AM was from 
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Calbiochem (La Jolla, CA). All other materials were obtained 
as described [3,4]. 
2.2. Methods 
Platelet-rich plasma from 200 ml of freshly drawn blood an- 
ticoagulated with 1/10 vol. of 3.8070 (w/v) trisodium citrate was 
incubated with aspirin (1 raM) for 15 rain at 37°C. PGI2 
(50 ng/ml) was then added, and platelets were pelleted by cen- 
trifugation at 800 x g for 10 rain. Platelets were resuspended in 
3 ml of a buffer prewarmed to 37°C (pH 7.4) containing Hepes 
(20 mM), NaCI (138 raM), KC1 (2.9 raM), MgC12 (1 raM), 
glucose (5 raM), autologous platelet-poor plasma (PPP, 2%), 
apyrase (3 U/ml ADPase) and PGEI (2 ~M), and were in- 
cubated with 3-4 mCi 32p for 1.5 h at 37°C. Then 20 ml of 
buffer containing 1mM EGTA were added, and platelets were 
pelleted by centrifugation (800 x g for 10 min). Platelets were 
resuspended in 10-15 ml of buffer without EGTA and PGE1, 
but containing apyrase (0.6 U ADPase/ml), and 2070 PPP. The 
platelet suspension was kept at room temperature. Samples 
(0.8 ml) were transferred into aggregometer cuvettes, and were 
incubated for 2 min at 37°C whilst stirring (1100 rpm) and then 
exposed to A23187 dissolved in DMSO. The final concentration 
of DMSO in the platelet sample was <0.2o70. Epinephrine or 
buffer was added 10-15 s before A23187. Aggregation was 
measured in a laboratory aggregometer. Aliquots (0.05 ml) 
were transferred either into 0.05 ml of sample buffer containing 
1 070 SDS and dithiothreitol (15 mg/ml) for measurement of pro- 
tein phosphorylation or into 0.375 ml chloroform/methanol 
(1:2) for determination of phosphatidic acid [3,4,13]. 
Phosphorylation or [32P]phosphorylation in control samples 
ranged in various experiments for the 20 kDa protein from 150 
to 650 cpm, for the 40 kDa protein from 180 to 750 cpm and 
for [32P]phosphatidic acid from 200 to 1000 cpm. Secretion of 
[3H]serotonin was measured as described [13]. Ca z+ mobiliza- 
tion was measured using Indo-l/AM as in [3]. 
2.3. Statistical analysis 
Statistical analysis was performed using Student's t-test for 
paired and unpaired ata. Results are expressed as means + SE 
where n = number of separate xperiments. 
3. RESULTS 
Epinephrine (10/~M), which by itself did not in- 
duce aggregation, added 10 s before A23187 in- 
creased several fold platelet aggregation induced 
by A23187. The potentiation of platelet aggrega- 
tion by epinephrine was particularly pronounced at 
250 nM A23187 (figs 1,2). Aggregation was par- 
tiaUy reversible and no secretion of serotonin was 
observed at that concentration of A23187. 
Epinephrine also potentiated the action of a higher 
concentration of A23187 (500 nM) on platelet ag- 
gregation without, however, increasing the amount 
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Fig.l. Potentiation of Ca 2+ ionophore A23187-induced platelet aggregation by epinephrine (10/~M). Suspensions of aspirinized, 
washed platelets labeled with [3H]serotonin were incubated at 37°C and stirred for 2 rain in aggregometer cuvettes, and then stimulated 
with various concentrations of A23187. Epi/lephrine which by itself did not induce platelet aggregation was added 10 s before A23187. 
Secretion of [3H]serotonin (070 of total, indicated in rectangles) was measured 2 min after addition of A23187. The experiment is
representative for at least ten other experiments. 
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Fig.2. Effect of epinephrine (10/~M) on [32p]phosphorylation of 20 kDa and 40 kDa proteins, formation of [32P]phosphatidic acid 
(PA) (left panel) and platelet aggregation (right panel) in platelets stimulated by A23187 (250 nM). Suspensions of aspirinized, washed 
platelets were prelabeled with 32p. Results are means ± SE from four experiments. A23187 alone (o-no); epinephrine for 10 s, then 
A23187 (e----e). Phosphorylation of 40 kDa protein was also not observed 20, 30 and 60 s after stimulation (not shown). 
of  serotonin released by that concentrat ion of 
A23187 (fig.l). 
A23187 induced the format ion of [32p]phospha- 
tidic acid. The increase did not occur before 5 s 
(not shown) and was found to be concentrat ion- 
dependent (fig.3). Pr ior addit ion of epinephrine 
potentiated phosphatidate format ion induced by 
A23187 (figs 2,3). After platelet activation with 
500 nM A23187, aggregation and format ion of 
phosphatidic acid were comparable to the values 
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Fig.3. Effect of epinephrine (10/~M) on aggregation, [a2p]phosphatidic acid formation, and [32p]phosphorylation of 20 and 40 kDa 
proteins in platelets stimulated by various concentrations of A23187. Phosphorylation f the 20 kDa protein was measured 3 s after 
addition of A23187, and phosphorylation f the 40 kDa protein 10 s after addition of ,~23187. Aggregation and phosphatidic acid 
were measured 30 s after addition of A23187. Symbols as in legend to fig.2. Results are means + SE from four experiments. 
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obtained after platelet activation with 250 nM 
A23187 plus epinephrine, indicating a close asso- 
ciation of the amount of phosphatidate production 
and platelet aggregation. 
A23187 (100 and 250 nM) stimulated the rapid 
(faster than 3 s) phosphorylation f the 20 kDa 
myosin light chain. A23187 at these concentrations 
did not stimulate the phosphorylation of the 
40 kDa substrate of protein kinase C (figs 2,3). 
Phosphorylation f the 40 kDa protein was found 
to be increased only after platelet stimulation with 
500nM A23187 (fig.3). Prior incubation of 
platelets with epinephrine nhanced the 20 kDa 
myosin light chain phosphorylation i duced by 
A23187 without affecting the 40 kDa protein 
phosphorylation. 
Epinephrine did not significantly affect Ca 2+ 
mobilization evoked by Ca 2+ ionophore. A23187 
(250 nM) increased the cytosolic Ca 2+ from 80 nM 
in resting platelets to 394 +_ 17 nM (maximum after 
10 s). Addition of epinephrine prior to 250 nM 
A23187 did not significantly increase this value 
further (424 _+ 36 nM; mean _+ SD, n = 3). 
4. DISCUSSION 
Epinephrine potentiated platelet aggregation 
and [3ZP]phosphatidate production i duced by the 
Ca 2+ ionophore A23187. [3ZP]Phosphatidate for- 
mation correlated closely with aggregation. The 
origin of phosphatidate formation after platelet 
stimulation with A23187 is obscure. Phospholipase 
C-induced breakdown of phosphoinositides is not 
involved, since the formation of endoperox- 
ides/thromboxane Az and ADP had been blocked 
[14]. Also, if traces of diglyceride were formed 
after A23187 stimulation of platelets, a large pro- 
tein kinase C activation would have been expected 
due to the priming of protein kinase C by the 
cytosolic Ca 2+ increase [3]. But no protein kinase 
C activation as measured by 40 kDa protein 
phosphorylation was found. Possible sources of 
[32p[phosphatidate formation in platelets stimulat- 
ed by A23187 are a stimulated conversion of 
diglyceride to phosphatidic a id or, more likely, an 
inhibition of the reconversion of phosphatidic a id 
to phosphatidylinositol. Interruption of the phos- 
phatidylinositol cycle by A23187 in platelets has 
been previously demonstrated [15]. Alternatively, 
[32p]phosphatidate could derive from phos- 
pholipid degradation by phospholipase D. Phos- 
pholipase D hydrolyzing phosphatidylinositol 
has recently been shown in neutrophils activated 
by A23187 [16]. Because pinephrine increased the 
production of phosphatidate after A23187 stimula- 
tion of platelets, one can speculate that a Gi- 
protein might be involved in the activation of 
phospholipase D. Evidence for a G-protein cou- 
pled to hormone-induced phospholipase D activa- 
tion has been presented in hepatocytes [17]. 
The close association of phosphatidic acid for- 
mation and aggregation is interesting. Phospha- 
tidic acid can translocate Ca z+ across organic 
phases [18] and, if added at micromolar concentra- 
tions to multilamellar liposomes, increases their 
permeability for Ca 2+ [19]. In addition, it has been 
shown that 1-oleoyl-2-acetylglycerol added to 
saponized platelets causes the mobilization of Ca z+ 
from the endoplasmic reticulum. This effect was 
found to be dependent on its conversion to phos- 
phatidic acid [20]. However, bioactive diacylgly- 
cerols added to intact platelets are also trans- 
formed to phosphatidic acid [21] but they do not 
increase cytosolic Ca 2+ [22]. Furthermore, inhibi- 
tion of diglyceride kinase by specific drugs in intact 
platelets enhances rather than inhibits platelet 
aggregation and secretion induced by exogenous 
diacylglycerols [23,24]. Thus, the function of 
phosphatidate for platelet aggregation is un- 
certain. 
Most surprising was the observation that the 
combination of epinephrine with a low concentra- 
tion of A23187 induced about 70% of maximal ag- 
gregation without any activation of protein kinase 
C. Previous studies [2,3,13,25-28] indicated the 
significance of protein kinase C in regulating 
platelet aggregation and secretion. The present 
results indicate that it is possible to circumvent that 
pathway by the synergistic interaction of Ca 2+ 
mobilization and cr2-adrenergic receptor activa- 
tion. ~2-Adrenergic receptors in platelets are 
coupled selectively to Gi [4,6-9]. Therefore, the 
novel synergism described in the present study 
seems to depend on Gi-protein activation and Ca 2+ 
mobilization. That synergism could be responsible 
for shape change and primary aggregation i duced 
by low concentrations of physiological stimuli. For 
example, ADP and the thromboxane Az analogs 
STA2 mobilize intracellular Ca 2+, their receptors 
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are coupled to Gi proteins [29,30], but  at low con- 
centrat ions they do not induce the phosphory lat ion 
o f  the 40 kDa protein [31,32]. 
In summary,  there may be at least three 
pathways in platelets which synergize with each 
other [1]: the Ca 2+ pathway that causes myosin 
l ight chain phosphory lat ion,  the protein kinase C 
pathway and an unknown pathway tr iggered by 
tr2-adrenergic receptor /G i -prote in  activation. 
Synergism has been demonstrated for each pair  of  
these pathways:  (a) Ca 2+ mobi l izat ion and protein 
kinase C act ivat ion [2,3], (b) epinephrine and pro-  
tein kinase C act ivat ion [5], and (c) epinephrine 
and Ca 2+ mobi l izat ion (this study). Interestingly, 
each pathway can synergize with the other in- 
dependent ly  o f  the third pathway.  The synergism 
of  the Ca 2+ pathway and the a¢2-adrenergic recep- 
to r /G i -prote in  pathway concerns platelet aggrega- 
t ion but  not secretion, and it is, in that regard, 
comparab le  to the synergism between the protein 
kinase C and Gi-protein pathways [5]. In contrast,  
the Ca 2+ and protein kinase C pathways ynergize 
in inducing both platelet aggregat ion and secretion 
[2,3]. 
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